PubMed Health⌕ Search

Biomedical subjects

J A Mahoudeau

Publications and source records attributed to J A Mahoudeau.

13 recordsLinked to original sources
PubMed1979

Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases.

In a study of nonsurgical therapy of Cushing's disease, 62 patients received O,p'-dichlorodiphenyldichloroethane (O,p'DDD), 16 of whom also received cobalt irradiation of the pituitary. After an initial treatment period averaging eight months, a remission of the disease was obtained in 38 of the 46 patients given O,p'DDD alone and in all patients who received drug combined with radiation. Although 60 per cent of these patients subsequently relapsed, additional courses of drug or radiation therapy were usually effective, and 63 per cent of the entire group of patients have so far been kept under control without adrenalectomy. (Forty patients have been followed for at least two years after the initial course of treatment.). O,p'DDD produced little gastrointestinal discomfort; an increased serum cholesterol was the main side effect. This drug allows long-term medical management of Cushings disease in most cases. Whether the combination of O'p'DDD with pituitary radiation is the best therapy has not been established.

17-Hydroxycorticosteroids↗
PubMed1977

Hormonal changes induced by bromocriptine (CB-154) at the early stage of treatment.

Fifteen female patients with amenorrhea and hyperprolactinemia were studied 1 to 3 times daily during the first 4 days of treatment with bromocriptine (2.5 mg b.i.d). Normal PRL levels were reached within one day in 12 while the mean value for the whole group showed no further significant decrease. Estradiol, LH and FSH levels did not vary significantly at this stage even in those 10 patients who subsequently resumed menstruation.

Adult↗
PubMed1977

Reversible gonadotropin deficiency in male Cushing's disease.

Twelve adult males with documented active Cushing's disease were studied. Mean plasma testosterone (T) was significantly decreased: 1.8 +/- 0.3 (SEM) ng/ml (N=6.8 +/- 0.5); gonadotropin measurements in 8 patients, in basal conditions and under LH-RH iv, showed a significant decrease in both FSH and LH. A further study of 11 patients in remission of Cushing's disease indicated a significant increase in plasma T and gonadotropins up to the normal range. One patient with an initial low T value had a normalized T while in remission, then a dramatic decrease when the disease relapsed. We conclude: a hypogonadotropic hypogonadism is found in male Cushing's disease; it disappears as early as hypercortisolism is suppressed. Some possible mechanisms are discussed.

Adolescent↗
PubMed1976

Release of immuno-reactive and biologically active LH from fetal mouse pituitary in response to synthetic gonadotropin releasing factor (LRF).

In an incubation system, LRF stimulated significantly the release of LH from 18-day-old mouse fetal pituitary. This LRF-induced LH release, measured by RIA in the incubation medium was able to increase the testosterone production by age-matched fetal testes. This data suggests that the hypothalamo-hypophyseal-testicular axis is functional at the end of mouse prenatal life.

Animals↗
PubMed1976

[Sexual side-effects of spironolactones. Possible mechanisms of their anti-androgen action].

Spirolactones (spironolactone, potassium canrenoate) may produce secundary sexual effects such as gynecomastia in man and menstrual disturbances in women. The mechanism of action of the antiandrogenic effects has been studied in man and rat. Acute i.v. injection of potassium canrenoate into man results in a decrease of plasma testosterone, without any change of gonadotropins. This decrease might be due to an impaired testicular steroidogenesis. On the other hand, spirolactones have an antiandrogenic effect at the target cells level. They do not modify the prostate 5alpha-reductase activity; however, they do inhibit the binding of androgens to their receptors. Thus the spirolactones interact with both biosynthesis and peripheral action of androgens.

Adult↗
PubMed1976

Demonstration of a pituitary gonadotrophin hormone activity in the male foetal mouse.

The testosterone production by 18-days-old foetal mouse testis was measured in an organ culture system, by RIA in the culture medium. This production was time-dependent, and could be stimulated by ovine LH and age-matched foetal pituitary. The gonadotrophin activity derived from foetal pituitary appeared to be released into the culture medium as a limited reserve. These data clearly show that a biologically active gonadotrophin material is present in the pituitary of the 18-days-old mouse foetus.

Adrenocorticotropic Hormone↗
PubMed1975

[Cryptorchism].

Explore the source record for details and available documents.

Cryptorchidism↗
PubMed1975

[The effect of gonadotropic hormones and the fetal hypophysis on testosterone production by the testis of 18 day mouse fetuses in organ culture].

The production of testosterone (measured by radioimmuno-assay) by the 18-day-old mouse fetal testis may be stimulated specifically by ovine LH (1 ng, p less than 0.005) and HCG in organ culture. A stimulation by FSH is observed only with high doses (10 mug, p less than 0.0005). Prolactin and ACTH have no effect. Age-matched fetal pituitaries increase significantly the testosterone production in the culture medium (p less than 0.0005).

Adrenocorticotropic Hormone↗
PubMedDate not supplied

[Study of Leydig cells and gonadotropin activity in 14-18 days old fetal mouse (author's transl)].

An organ culture system has been developed for mouse embryo testes and pituitaries at 14-18 days of gestation. The testosterone (T) production by fetal testes has been measured by RIA in the culture medium: it increases from day 14 to day 18 and may be specifically stimulated by ovine LH and hCG. Fetal pituitaries in culture release a gonadotropin activity at 16 and 18 days (not found at 14 days), which is detectable by an heterologous RIA of LH and by a significant increase in T production from age-matched testes in co-culture. The 18-days old pituitaries respond to synthetic LH-RH by an enhanced production of immunologically and biologically active LH.

Animals↗